ANIK · Anika Therapeutics, Inc.

Anika Therapeutics delivered a materially improved Q1 2026 performance, marked by double-digit top-line growth and a significant gross margin expansion of 810 basis points to 64.2%, the highest in recent history. This improvement was driven by stronger operational execution, favorable product mix, and ongoing margin initiatives—including lean manufacturing deployment—rather than pricing or one-time benefits. Revenue growth was balanced across both channels: OEM Channel rose 14% to $17.0 million, aided by favorable order timing and continued Monovisc demand, while Commercial Channel grew 12% to $12.6 million, led by 20% growth in Regenerative Solutions and 35% U.S. procedure growth for Integrity. Adjusted EBITDA surged to $4.3 million—$4.2 million higher than last year—despite $4.9 million in one-time severance costs, underscoring the leverage in Anika’s business model as volume scales. Management explicitly tied this progress to its strategic transformation and organizational realignment, citing early wins in productivity and scalability. The company maintained full-year 2026 guidance, projecting revenue between $114–$122.5 million and Adjusted EBITDA as 5–10% of revenue, acknowledging modestly lower U.S. pricing dynamics as a headwind. Concurrently, the resignation of two long-standing directors—Jellison and Larsen—signals governance evolution aligned with the company’s transformation, though the Board reduction from nine to seven members is procedural rather than reactive. Completion of the $15 million 10b5-1 buyback further reflects financial discipline and confidence in near-term cash flow generation and valuation. Collectively, these developments indicate a decisive inflection toward sustainable, profitable growth—particularly as clinical catalysts (Hyalofast PMA, Cingal NDA) advance toward potential regulatory milestones later in 2026.